Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNPGet Rating) in a research report issued on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Up 3.2 %

TTNP opened at $0.91 on Monday. Titan Pharmaceuticals has a one year low of $0.35 and a one year high of $1.59. The business’s 50-day simple moving average is $0.89 and its 200-day simple moving average is $1.10.

Institutional Trading of Titan Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC purchased a new position in Titan Pharmaceuticals in the 3rd quarter valued at about $30,000. State Street Corp purchased a new position in Titan Pharmaceuticals in the 3rd quarter valued at about $41,000. Millennium Management LLC boosted its position in Titan Pharmaceuticals by 516.8% in the 2nd quarter. Millennium Management LLC now owns 63,106 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 52,874 shares during the last quarter. Virtu Financial LLC purchased a new position in Titan Pharmaceuticals in the 2nd quarter valued at about $35,000. Finally, Renaissance Technologies LLC boosted its position in Titan Pharmaceuticals by 559.3% in the 2nd quarter. Renaissance Technologies LLC now owns 240,710 shares of the specialty pharmaceutical company’s stock valued at $135,000 after buying an additional 204,200 shares during the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.

About Titan Pharmaceuticals

(Get Rating)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union.

Recommended Stories

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.